8-K
filed May 23, 2023, 7:59 PM ET
ticker RMTI
CIK 0001041024
other material
confidence high
sentiment neutral
materiality 0.15
Rockwell Medical shareholders elect directors, approve 1.6M share equity plan increase
ROCKWELL MEDICAL, INC.
- Mark Ravich and Andrea Heslin Smiley elected Class II directors; Ravich received 2,015,069 for, 873,941 against; Smiley 2,639,034 for, 249,295 against.
- Advisory vote on executive compensation approved: 2,485,037 for, 337,531 against.
- Frequency of say-on-pay set at 1 year (2,704,562 votes for 1 year).
- Ratification of EisnerAmper LLP as auditor for 2023: 7,696,517 for, 119,313 against.
- Amendment to 2018 Long Term Incentive Plan to increase reserved shares by 1,600,000 approved: 1,994,126 for, 825,079 against.
Key facts
Extracted from this filing and checked against the source text.
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
ROCKWELL MEDICAL, INC. shareholders approved To approve, on an advisory basis, the compensation of the Company's named executive officers. at the 2023-05-23 meeting.
- Proposal
- say on pay
- Outcome
- passed
- Meeting
- 2023-05-23
Exact text from the filing
Proposal Two: To approve, on an advisory basis, the compensation of the Company's named executive officers. For Against Abstain Broker Non-Votes 2,485,037 337,531 103,205 4,932,013
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
ROCKWELL MEDICAL, INC. shareholders approved To approve, on an advisory basis, the frequency of stockholder advisory votes on compensation of the Company's named executive officers. at the 2023-05-23 meeting.
- Proposal
- say on pay frequency
- Outcome
- passed
- Meeting
- 2023-05-23
Exact text from the filing
Proposal Three: To approve, on an advisory basis, the frequency of stockholder advisory votes on compensation of the Company's named executive officers. 1 Year 2 Years 3 Years Abstain Broker Non-Votes 2,704,562 69,060 95,135 57,016 4,932,013
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
ROCKWELL MEDICAL, INC. shareholders approved To approve an amendment and restatement of the Rockwell Medical, Inc. 2018 Long Term Incentive Plan to increase the number of shares reserved for issuance thereunder by 1,600,000 shares. at the 2023-05-23 meeting.
- Proposal
- equity plan
- Outcome
- passed
- Meeting
- 2023-05-23
Exact text from the filing
Proposal Five: To approve an amendment and restatement of the Rockwell Medical, Inc. 2018 Long Term Incentive Plan to increase the number of shares reserved for issuance thereunder by 1,600,000 shares. For Against Abstain Broker Non-Votes 1,994,126 825,079 106,568 4,932,013
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
ROCKWELL MEDICAL, INC. shareholders approved To ratify the selection of EisnerAmper LLP as the Company’s independent registered public accounting firm for 2023. at the 2023-05-23 meeting.
- Proposal
- auditor ratification
- Outcome
- passed
- Meeting
- 2023-05-23
Exact text from the filing
Proposal Four: To ratify the selection of EisnerAmper LLP as the Company’s independent registered public accounting firm for 2023. For Against Abstain 7,696,517 119,313 41,956
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
ROCKWELL MEDICAL, INC. shareholders approved To elect the two Class II directors to serve for a three-year term expiring at the 2026 annual meeting of stockholders and until his or her successor has been duly elected and qualified. at the 2023-05-23 meeting.
- Proposal
- director election
- Outcome
- passed
- Meeting
- 2023-05-23
Exact text from the filing
Proposal One: To elect the two Class II directors to serve for a three-year term expiring at the 2026 annual meeting of stockholders and until his or her successor has been duly elected and qualified. For Against Abstain Broker Non-Votes Mark Ravich 2,015,069 873,941 36,763 4,932,013 Andrea Heslin Smiley 2,639,034 249,295 37,444 4,932,013
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.